Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.43 |
| ▸ | CA2 | P00918 | 9/20 | 0.43 |
| ▸ | CA12 | O43570 | 6/20 | 0.41 |
| ▸ | CA9 | Q16790 | 6/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20836740 | 0.87 | CA2 (0.46) | CA1CA2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL27446329 | 0.86 | CA1 (0.42) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL21100862 | 0.82 | CA1 (0.42) | CA1CA2CA12CA9BCHE | |
| SCHEMBL21479563 | 0.81 | ABCG2 (0.40) | CA1CA2CA12CA9BCHE | |
| SCHEMBL10177832 | 0.81 | CA1 (0.47) | CA1CA2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15010853 | 0.80 | CA1 (0.42) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL12187846 | 0.80 | CA1 (0.42) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL12187832 | 0.80 | CA1 (0.42) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL20836747 | 0.79 | CA2 (0.51) | CA1CA2CA12CA9KMT2A | |
| SCHEMBL26938534 | 0.79 | POLB (0.47) | CA1CA2CA12CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11077082-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS, LLC (US) | 2021-08-03 | — | — | US | disclosed |
| US-10328043-B1 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS, LLC. (US) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10328043-B1 | Composition and method for dual targeting in treatment of neuroendocrine tumors | THRB, TSHR, SLC6A2 | CA1 2121/4885CA2 1756/4885CA12 1236/4885 |
| US-11077082-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | THRB, TSHR, SLC6A2 | CA1 2121/4885CA2 1756/4885CA12 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.